Nothing Special   »   [go: up one dir, main page]

DE60031456D1 - Rekombinante alpha-l-iduronisase, deren herstellungs- und aufreinigungsverfahren, und behandlung von durch diese hervorgerufene mangelerkrankungen - Google Patents

Rekombinante alpha-l-iduronisase, deren herstellungs- und aufreinigungsverfahren, und behandlung von durch diese hervorgerufene mangelerkrankungen

Info

Publication number
DE60031456D1
DE60031456D1 DE60031456T DE60031456T DE60031456D1 DE 60031456 D1 DE60031456 D1 DE 60031456D1 DE 60031456 T DE60031456 T DE 60031456T DE 60031456 T DE60031456 T DE 60031456T DE 60031456 D1 DE60031456 D1 DE 60031456D1
Authority
DE
Germany
Prior art keywords
iduronisase
suffered
treatment
production
purification method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60031456T
Other languages
English (en)
Other versions
DE60031456T2 (de
Inventor
John M Henstrand
Minmin Qin
Wia-Pan Chan
Lin Chen
Paul A Fitzpatrick
Dan J Wendt
Gary N Zecherle
Christopher M Starr
Emil D Kakkis
Becky Tanamachi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Harbor Ucla Medical Center
LA BioMed (The Los Angeles Biomedical Res Inst)
Original Assignee
Biomarin Pharmaceutical Inc
Harbor Ucla Medical Center
LA BioMed (The Los Angeles Biomedical Res Inst)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc, Harbor Ucla Medical Center, LA BioMed (The Los Angeles Biomedical Res Inst) filed Critical Biomarin Pharmaceutical Inc
Application granted granted Critical
Publication of DE60031456D1 publication Critical patent/DE60031456D1/de
Publication of DE60031456T2 publication Critical patent/DE60031456T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01014—Chitinase (3.2.1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01075—Glucan endo-1,6-beta-glucosidase (3.2.1.75)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE60031456T 1999-11-12 2000-11-09 Rekombinante alpha-l-iduronisase, deren herstellungs- und aufreinigungsverfahren, und behandlung von durch diese hervorgerufene mangelerkrankungen Expired - Lifetime DE60031456T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/439,923 US6426208B1 (en) 1999-11-12 1999-11-12 Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US439923 1999-11-12
PCT/US2000/031293 WO2002004616A1 (en) 1999-11-12 2000-11-09 RECOMBINANT α-L-IDURONIDASE, METHODS FOR PRODUCING AND PURIFYING THE SAME AND METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES THEREOF

Publications (2)

Publication Number Publication Date
DE60031456D1 true DE60031456D1 (de) 2006-11-30
DE60031456T2 DE60031456T2 (de) 2007-08-23

Family

ID=23746702

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60031456T Expired - Lifetime DE60031456T2 (de) 1999-11-12 2000-11-09 Rekombinante alpha-l-iduronisase, deren herstellungs- und aufreinigungsverfahren, und behandlung von durch diese hervorgerufene mangelerkrankungen
DE60042137T Expired - Lifetime DE60042137D1 (de) 1999-11-12 2000-11-09 Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60042137T Expired - Lifetime DE60042137D1 (de) 1999-11-12 2000-11-09 Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen

Country Status (15)

Country Link
US (3) US6426208B1 (de)
EP (2) EP1332206B1 (de)
JP (3) JP2004502456A (de)
CN (2) CN101407796A (de)
AT (2) ATE430193T1 (de)
AU (2) AU773663B2 (de)
BR (1) BRPI0015533B8 (de)
CA (1) CA2391098C (de)
DE (2) DE60031456T2 (de)
ES (2) ES2324727T3 (de)
HK (2) HK1057059A1 (de)
IL (3) IL149568A0 (de)
MX (1) MXPA02004742A (de)
WO (1) WO2002004616A1 (de)
ZA (1) ZA200203619B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6585971B1 (en) * 1999-11-12 2003-07-01 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
US6569661B1 (en) * 1999-11-12 2003-05-27 Biomarin Pharmaceutical Inc. Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
EP1368039A4 (de) * 2001-02-20 2006-03-29 Uab Research Foundation Aminoglycosid-behandlung für lysosomale speicherkrankheiten
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
WO2005021716A2 (en) * 2003-08-21 2005-03-10 Q Therapeutics, Inc. Genetically modified somatic cells for sustained secretion of lysosomal proenzymes deficient in lysosomal storage disorders
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
WO2007035716A2 (en) 2005-09-16 2007-03-29 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
WO2007065273A1 (en) * 2005-12-08 2007-06-14 The University Of British Columbia Mucopolysaccharidosis (mps) diagnostic methods, systems, kits and assays associated therewith
ATE539089T1 (de) * 2007-03-21 2012-01-15 Raptor Pharmaceutical Inc Cyclische rezeptor-assoziierte-proteine (rap)- peptide
EP2188302B1 (de) 2007-07-09 2017-11-01 Genentech, Inc. Verhinderung der reduktion der disulfidbindung während der rekombinanten herstellung von polypeptiden
EP2093085B1 (de) * 2008-02-21 2012-05-02 Fiat Group Automobiles S.p.A. Glasstützbaueinheit für eine Kraftfahrzeugtür mit einer ungerahmten oberen Kante
EP3187508A1 (de) 2008-05-07 2017-07-05 BioMarin Pharmaceutical Inc. Auf lysosomen gerichtete peptide und verwendungen davon
EP2475376B1 (de) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulierungen für lysosomale enzyme
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
DE102011102170B4 (de) 2011-05-20 2024-06-06 Vitesco Technologies GmbH Einspritzvorrichtung zur Einspritzung eines Fluids
BR112014031788A2 (pt) 2012-06-19 2017-06-27 Univ Florida composições e métodos para o tratamento de diabetes
US9086580B2 (en) 2012-08-10 2015-07-21 Osio Corporation Contact lens use in the treatment of an ophthalmologic condition
HUE051373T2 (hu) * 2013-03-15 2021-03-01 Univ Pennsylvania Készítmények MPSI kezelésére
EP3411488A1 (de) 2016-02-03 2018-12-12 The Trustees Of The University Of Pennsylvania Gentherapie zur behandlung von mukopolysaccharidose typ i
CA3049915A1 (en) * 2017-01-31 2018-08-09 Stephen YOO Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)
EP3676385A1 (de) 2017-07-06 2020-07-08 The Trustees of The University of Pennsylvania Aav9-vermittelte gentherapie zur behandlung von mukopolysaccharidose typ i
CA3076036A1 (en) 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
CN107699590A (zh) * 2017-10-13 2018-02-16 成都中医药大学 一种制备重组人α‑L‑艾杜糖醛酸酶的方法
WO2020132100A1 (en) 2018-12-19 2020-06-25 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules for lysosomal targeting and related compositions and methods
CN110577559B (zh) * 2019-08-19 2023-02-17 江西科技师范大学 α-L-艾杜糖醛酸酶测定用荧光糖苷酶底物的合成方法
WO2022145449A1 (ja) * 2021-01-04 2022-07-07 国立大学法人徳島大学 ライソゾームを標的とした新規ｄｄｓの開発
CN115109790A (zh) * 2021-03-23 2022-09-27 北京据德医药科技有限公司 一种重组a-L-艾杜糖醛酸普酶及其制备方法
CN114181318B (zh) * 2021-11-08 2023-08-01 四川大学 一种组织特异性表达穿透血脑屏障的idua融合蛋白的重组腺相关病毒及应用
CN115161284B (zh) * 2022-07-04 2024-07-09 无锡多宁生物科技有限公司 一种lmh悬浮细胞复苏培养方法及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL281225A (de) 1961-07-20
GB1029548A (en) 1963-07-17 1966-05-11 Amagasaki Iron & Steel Mfg Co Corrugated roofing sheet
US3472931A (en) 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3891757A (en) 1971-11-11 1975-06-24 Alza Corp Anaesthetic topical and percutaneous administration with selected promoters
US5270051A (en) 1991-10-15 1993-12-14 Harris Donald H Enzyme-orthokeratology
US6149909A (en) * 1995-06-23 2000-11-21 Women's And Children's Hospital Synthetic α-L-iduronidase and genetic sequences encoding same
CA2099503C (en) 1991-11-14 2007-10-09 Hamish Steele Scott Synthetic alpha-l-iduronidase and genetic sequences encoding same
US5278051A (en) * 1991-12-12 1994-01-11 New York University Construction of geometrical objects from polynucleotides
EP0865499B1 (de) 1995-09-14 2009-03-18 Virginia Tech Intellectual Properties, Inc. Produktion von lysosomalen enzymen in pflanzlichen expressionssystemen
GB9807464D0 (en) 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
EP1078075A2 (de) 1998-05-13 2001-02-28 Harbor-Ucla Research and Education Institute Rekombinante (alpha)-l-iduronidase, deren herstellungs- und aufreinigungs-verfahren, und verfahren zur behandlung von durch diese hervorgerufene mangelerkrankungen

Also Published As

Publication number Publication date
ZA200203619B (en) 2003-07-30
DE60042137D1 (de) 2009-06-10
BR0015533A (pt) 2002-06-25
IL149568A0 (en) 2002-11-10
US6426208B1 (en) 2002-07-30
ES2273748T3 (es) 2007-05-16
DE60031456T2 (de) 2007-08-23
EP1332206B1 (de) 2006-10-18
CN1420924A (zh) 2003-05-28
CN1420924B (zh) 2010-05-05
WO2002004616A1 (en) 2002-01-17
IL149568A (en) 2010-04-29
US20060286087A1 (en) 2006-12-21
AU2004208651A1 (en) 2004-09-30
IL192078A (en) 2011-06-30
JP3857705B2 (ja) 2006-12-13
CA2391098C (en) 2007-10-23
BRPI0015533B8 (pt) 2021-05-25
JP2005046154A (ja) 2005-02-24
AU8463501A (en) 2002-01-21
EP1792983A1 (de) 2007-06-06
BRPI0015533B1 (pt) 2020-12-08
IL192078A0 (en) 2008-12-29
CA2391098A1 (en) 2002-01-17
EP1332206A1 (de) 2003-08-06
AU773663B2 (en) 2004-06-03
MXPA02004742A (es) 2005-09-08
HK1104836A1 (en) 2008-01-25
EP1792983B1 (de) 2009-04-29
ATE430193T1 (de) 2009-05-15
JP2006312648A (ja) 2006-11-16
ATE342964T1 (de) 2006-11-15
JP2004502456A (ja) 2004-01-29
HK1057059A1 (en) 2004-03-12
ES2324727T3 (es) 2009-08-13
CN101407796A (zh) 2009-04-15
US20030013179A1 (en) 2003-01-16
US7041487B2 (en) 2006-05-09

Similar Documents

Publication Publication Date Title
DE60031456D1 (de) Rekombinante alpha-l-iduronisase, deren herstellungs- und aufreinigungsverfahren, und behandlung von durch diese hervorgerufene mangelerkrankungen
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
ATE211392T1 (de) Verwendung des glialen, neurotrophen faktors (gdnf) zur behandlung von gehörstörungen
ATE202940T1 (de) Mittel und methoden zur behandlung von plaque- krankheiten
IL143313A0 (en) Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases
TR200101307T2 (tr) Antranilik asit amidler ve ilaç olarak kullanılmaları.
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
BG105012A (en) N-linked sulphonamides of n-heterocyclic carboxylic acids or carboxylic isosteres
NO20002702L (no) Tienopyrimidiner
NO985297L (no) FremgangsmÕte for fremstilling av et rekombinant polypeptid omfattende tils
ATE289800T1 (de) Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems
WO1999058691A3 (en) Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
ATE85523T1 (de) Taurohyodeoxycholsaeure zur behandlung von gallenwegssteinen und gallenstoerungen.
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE69426471D1 (de) Verwendung von Sulodexid und von Arzneimitteln, die dieses enthalten, zur Behandlung der diabetischen Nephropathie
DE69933218D1 (de) Methode zur behandlung von krankheiten durch veränderung der wechselwirkung zwischen natural killer rezeptoren auf t-zellen mit ihren jeweiligen liganden
ATE355057T1 (de) Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen
WO2004043373A3 (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
BG105014A (en) Ureas and carbamates of n-heterocyclic carboxylic acids and carboxylic acid isosteres
ATE402253T1 (de) Humane adulte astrozyten, sowie deren herstellung und verwendung
HUP0103712A2 (hu) Paroxetin sók, eljárás az előállításukra és gyógyászati alkalmazásuk
ATE271881T1 (de) Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen
DE69736180D1 (de) Behandlung von manischen erkrankungen
WO2003056897A3 (en) Highly phosphorylated acid beta-glucocerebrosidase and methods of treating gaucher's disease
DE60213219D1 (de) Verwendung von thiolutin dioxide und ihren derivaten zur herstellung eines arzneimittels zur behandlung von zns-krankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition